Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 in Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
NCT06621888Phase 2Completed
- Sponsor
- Fenix Innovation Group
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NTI164 in pediatric acute-onset neuropsychiatric syndrome (PANS), sponsored by Fenix Innovation Group. Primary endpoints: Clinical Global Impression Scale-Improvement at 52 weeks and Revised Childrens Anxiety and Depression Scale-Parent Version at 52 weeks. Started Jun 2023; status: completed.
02
Drugs
NTI164
03
Conditions
pediatric acute-onset neuropsychiatric syndrome (PANS)
Beyond the preview
Go deeper on NCT06621888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621888.